ResearchMoz

Omalizumab - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Publisher Name » GenericsWeb
Published Date » 2011-12-01
No. Of Pages » N/A

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Omalizumab

Examples of information found in this online report include:

  • Includes key patent publications for 44 countries (see list below)
  • Contains SPC protection for every EU state plus patent term extensions in other countries
  • Data exclusivity calculated on a country by country basis
  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
  • DMF & Paragraph IV filings
  • Litigation alerts
  • Marketing authorisation holders in selected territories
  • Patent risk analysis via graphical display of data from patent filings
  • Hyper-linking to crucial patent documents and national registries enabling data verification
The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

  • Country Region Extensions
  • Australia Asia-Pacific S70
  • Canada Americas N/A
  • USA Americas S156
  • Germany Western Europe SPC
  • Great Britain Western Europe SPCS
  • France Western Europe NAT/SPC
  • Spain Western Europe SPC
  • South Africa Africa N/A
  • China Asia-Pacific N/A
  • Japan Asia-Pacific S67
  • New Zealand Asia-Pacific N/A
  • Bosnia & Herzegovina Balkan N/A
  • Bulgaria Balkan SPC
  • Croatia Balkan N/A
  • Romania Balkan SPC
  • Slovenia Balkan NAT/SPC
  • Estonia Baltic NAT/SPC
  • Lithuania Baltic NAT/SPC
  • Latvia Baltic NAT/SPC
  • Czech Republic Central Europe NAT/SPC
  • Hungary Central Europe SPC
  • Poland Central Europe SPC
  • Slovakia Central Europe NAT/SPC
  • Serbia & Montenegro Central Europe N/A
  • Cyprus Mediterranean NAT/SPC
  • Greece Mediterranean SPC
  • Israel Mediterranean NAT
  • Malta Mediterranean SPC
  • Turkey Mediterranean N/A
  • Denmark Scandinavia SPC
  • Finland Scandinavia SPC
  • Iceland Scandinavia SPC
  • Norway Scandinavia SPC
  • Sweden Scandinavia SPC
  • Brazil South America N/A
  • Mexico South America N/A
  • Austria Western Europe SPC
  • Belgium Western Europe SPC
  • Switzerland Western Europe NAT/SPC
  • Ireland Western Europe SPC
  • Italy Western Europe NAT/SPC
  • Luxembourg Western Europe SPC
  • The Netherlands Western Europe SPC
  • Portugal Western Europe SPC
Other key information contained in the report:

  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**. 
  • News articles
  • Litigation alerts
  • Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
  • US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
  • Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
  • 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.
Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report). 

General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.

Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. 

# Includes key patent publications for 44 countries 
# Contains SPC protection for every EU state plus patent term extensions in other countries
# Data exclusivity calculated on a country by country basis
# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
# DMF & Paragraph IV filings
# Litigation alerts
# Marketing authorisation holders in selected territories
# Patent risk analysis via graphical display of data from patent filings
# Hyper-linking to crucial patent documents and national registries enabling data verification

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Corrosion Inhibitors Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2012 - 2018
By - Transparency Market Research
A corrosion inhibitor is a chemical compound that curbs the corrosion rate of a material, especially an alloy or a metal. The corrosion rate can be reduced by adding some material that reduces the corrosion rate and prevents the metal or alloy from further degradation. The corrosion rate is dampened depending on the effectiveness and quantity of the corrosion-inhibiting material. Such material is utilized in order to extend the shelf life and retain the tensile strength of the materials for a longer duration. The market is experiencing a dampened growth rate in developed...
Catalyst Regeneration Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Catalyst regeneration is the process used for producing aromatic hydrocarbons which are used as motor fuel. This process is mostly used by petroleum and petrochemical industries to convert paraffins and naphthenes into aromatics. With the increasing need for sulfur free clean fuel, regenerated catalyst usage is increasing. Global consumption of regenerated catalyst has reached around 1,200 kilo tons per year. Regeneration and recycling of catalysts will help petroleum refiners, chemical producers, power plant operators, and crude oil refineries in cost optimization and meet the...
Opportunities of Composites in the Global Automotive Market - Global Industry Size, Market Share, Trends, Analysis, and Forecast, 2012 - 2018
By - Transparency Market Research
Composites (glass fibers, resins, and carbon fibers) find their application in several sectors of the global market including the automotive market. There are several benefits of using composites in vehicles. It renders greater resistance to heat, makes the car lighter, and improves the fuel efficiency of the vehicle. New infrastructure projects, growth in population, environmental awareness, and urbanization are some of the factors likely to drive the market of composites in the automotive industry. Some of the factors hampering the growth of composites in the automotive...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...